Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment
Year: 2021
Type: conference-abstract
Source: Blood
Authors: David C. Dale, Laia Alsina, Antoine Azar, Raffaele Badolato, Ashish Bhandari, Andrea Belschner, Yves Bertrand, Diego Cadavid, Kathryn E. Dickerson, Navid Ezra, Henrik Hasle, Harold Hoffman, Honghua Jiang, Hyoung Jin Kang, Sorena Kiani-Alikhan, Taco W. Kuijpers, Aleksandr D. Kulagin, Daman Langguth, Carina Levin, Richard MacLeod, Olaf Neth, Jane Peake, Yulia Rodina, Anjali Sharathkumar, Anna Shcherbina, Weihua Tang, Matthias G. Vossen, Jean Donadieu
Institutions: University of Washington, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Sant Joan de Déu, Johns Hopkins University, University of Brescia, X4 Pharmaceuticals, Inc. (United States), Hospices Civils de Lyon, The University of Texas Southwestern Medical Center, Aarhus University Hospital, University of California San Diego, Rady Children's Hospital-San Diego, Seoul National University Hospital, Seoul National University Children's Hospital, Barts Health NHS Trust, Amsterdam University Medical Centers, Sullivan Nicolaides Pathology, Technion – Israel Institute of Technology, Emek Medical Center, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Children's Health Queensland Hospital and Health Service, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, University of Iowa, Medical University of Vienna, Hôpital Armand-Trousseau
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3215262484